Cat.No. : CSC-RO0650 Host Cell: HEK293
| Cat. No. | CSC-RO0650 |
| Description | This cell line is engineered to stably co-express human GDNF family receptor alpha like (GFRAL) and human ret proto-oncogene (RET). |
| Gene | GFRAL/RET |
| Host Cell | HEK293 |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Media Type | Cells were cultured in DMEM supplemented with 10% fetal bovine serum. |
| Freeze Medium | Complete medium supplemented with 10% (v/v) DMSO |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:3-1:6. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Chemotherapy-treated cancer patients develop cachexia along with anorexia, body weight loss, and the loss of adipose and skeletal muscle tissue. The scientists used combinatorial antibody phage library biopanning to create A11, a completely human GFRAL antagonist antibody. Serum response element-luciferase reporter activity was significantly reduced (up to 74%) indicating that A11 effectively suppressed GDF15-induced signaling. In a melanoma mouse model, A11 treatment alleviated anorexia and body weight loss by lowering GFRAL-positive neuron populations and attenuating the effects of cisplatin-induced GDF15 on the brainstem in vivo. Furthermore, A11 lessened the cisplatin-induced depletion of skeletal muscle and adipose tissue, indicating its promise as a treatment approach for chemotherapy-induced cachexia.
Figure 1. The researchers established a GFRAL/RET Stable Cell Line - HEK293 to investigate antibody A11's impact on inhibiting GDF15/GFRAL/RET axis signaling. Experimental methods included SPR, flow cytometry, immunostaining, and Western blot analysis. (Lee BY, et al., 2023)
A: The Human GFRAL/RET Stable Cell Line - HEK293, by stably expressing GFRAL and RET receptors in HEK293 cells, provides an experimental platform to study the roles of these receptors in tumor development. This cell line enables scientists to simulate a tumor cell environment and investigate how the activation of GFRAL and RET receptors affects cell proliferation, differentiation, and apoptosis. This is crucial for developing targeted therapeutic strategies against these receptors.
A: The Human GFRAL/RET Stable Cell Line - HEK293 serves as a model for drug screening to help scientists screen and validate inhibitors targeting RET kinase. By testing compounds in these cells, researchers can evaluate their effects on RET kinase activity, leading to the discovery of potential anticancer drug candidates, which is significant for treating cancers associated with RET mutations.
A: The Human GFRAL/RET Stable Cell Line - HEK293 can be used to study the roles of GFRAL and RET receptors in neural development, particularly in neuronal differentiation and synapse formation. This cell line helps scientists understand how these receptors affect neural cell signaling and function, providing new perspectives for the treatment of neural development-related diseases.
A: By stably expressing these receptors, the Human GFRAL/RET Stable Cell Line - HEK293 offers a controlled environment to study GFRAL and RET receptor-mediated cell signaling. This cell line allows researchers to analyze signaling pathways at the molecular level in detail, including receptor activation, downstream signaling molecule activation, and how these signals affect cell behavior.
A: Ensuring the accuracy of experiments when studying apoptosis with the Human GFRAL/RET Stable Cell Line - HEK293 relies on standardizing experimental conditions, including cell culture, drug treatment, and apoptosis detection methods. Additionally, using control groups and replicate experiments can enhance data reliability. These methods allow researchers to more accurately assess the roles of GFRAL and RET receptors in the apoptotic process.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human GFRAL/RET Stable Cell Line - HEK293 efficiently expresses GFRAL and RET genes, providing a powerful tool for studying their functions.
This cell line serves as a versatile platform for studying signal transduction and protein interactions, widely applied in various biological experiments.
The HEK293 cell line excels in virus packaging research, aiding in the development of novel viral vectors.
The Human GFRAL/RET Stable Cell Line provides a stable cellular model for studying related diseases, advancing the elucidation of disease mechanisms.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
